Table 1.
VEGFR2 expression (cancer vs. normal) in other datasets of Oncomine.
| Datasets | Subtype | P value | t-test | Fold change | N |
|---|---|---|---|---|---|
| Lu ovarian | Serous | 0.007 | -3.921 | -1.622 | 20 |
| Mucinous | 0.007 | -3.453 | -1.592 | 9 | |
| Endometrioid | 0.009 | -3.514 | -1.562 | 9 | |
| Clear cell | 0.013 | -2.902 | -1.480 | 7 | |
|
| |||||
| TCGA ovarian | Serous | 0.002 | -3.997 | -1.708 | 586 |
|
| |||||
| Yoshihara ovarian | Serous | 8.33E-4 | -3.460 | -2.572 | 22 |
|
| |||||
| Adib ovarian | Serous | 0.015 | -3.044 | -1.406 | 6 |
|
| |||||
| Hendrix ovarian | Serous | 0.033 | -2.580 | -1.137 | 41 |
| Mucinous | 0.118 | -1.313 | -1.078 | 13 | |
| Endometrioid | 0.058 | -2.075 | -1.107 | 37 | |
| Clear cell | 0.157 | -1.095 | -1.065 | 8 | |
Notes: the bold font indicates the difference was significant statistically. The negative value of fold change represents that VEGFR2 expression was downregulated. N: number of patients.